
Aaron Nilsen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4228641/publications.pdf Version: 2024-02-01



AADON NUSEN

#	Article	IF	CITATIONS
1	Identification and Characterization of Small-Molecule IRF3-Dependent Immune Activators for Pharmaceutical Development. ACS Chemical Biology, 2022, 17, 1073-1081.	3.4	Ο
2	Structure-activity relationships of <i>Toxoplasma gondii</i> cytochrome <i>bc</i> ₁ inhibitors. Expert Opinion on Drug Discovery, 2022, 17, 997-1011.	5.0	1
3	New Scalable Synthetic Routes to ELQ-300 , ELQ-316 , and Other Antiparasitic Quinolones. Organic Process Research and Development, 2021, 25, 1841-1852.	2.7	10
4	Characterization of a Novel Compound That Stimulates STING-Mediated Innate Immune Activity in an Allele-Specific Manner. Frontiers in Immunology, 2020, 11, 1430.	4.8	7
5	Affinity, potency, efficacy, selectivity, and molecular modeling of substituted fentanyls at opioid receptors. Biochemical Pharmacology, 2020, 182, 114293.	4.4	30
6	Endochin-like quinolone-300 and ELQ-316 inhibit Babesia bovis, B. bigemina, B. caballi and Theileria equi. Parasites and Vectors, 2020, 13, 606.	2.5	9
7	Novel Endochin-Like Quinolones Exhibit Potent <i>In Vitro</i> Activity against Plasmodium knowlesi but Do Not Synergize with Proguanil. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	12
8	Orally Bioavailable Endochin-Like Quinolone Carbonate Ester Prodrug Reduces Toxoplasma gondii Brain Cysts. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	21
9	Activities of Endochin-Like Quinolones Against in vitro Cultured Besnoitia besnoiti Tachyzoites. Frontiers in Veterinary Science, 2020, 7, 96.	2.2	12
10	Improving solubility and oral bioavailability of a novel antimalarial prodrug: comparing spray-dried dispersions with self-emulsifying drug delivery systems. Pharmaceutical Development and Technology, 2020, 25, 625-639.	2.4	15
11	Secondâ€Generation Inhibitors of the Mitochondrial Permeability Transition Pore with Improved Plasma Stability. ChemMedChem, 2019, 14, 1771-1782.	3.2	18
12	4′â€₽hosphopantetheine corrects CoA, iron, and dopamine metabolic defects in mammalian models of <scp>PKAN</scp> . EMBO Molecular Medicine, 2019, 11, e10489.	6.9	53
13	ELQ-331 as a prototype for extremely durable chemoprotection against malaria. Malaria Journal, 2019, 18, 291.	2.3	17
14	Targeting mitochondria in cancer therapy could provide a basis for the selective anti-cancer activity. PLoS ONE, 2019, 14, e0205623.	2.5	17
15	Mitochondrial type II NADH dehydrogenase of Plasmodium falciparum (PfNDH2) is dispensable in the asexual blood stages. PLoS ONE, 2019, 14, e0214023.	2.5	29
16	Emerging Alphaviruses Are Sensitive to Cellular States Induced by a Novel Small-Molecule Agonist of the STING Pathway. Journal of Virology, 2018, 92, .	3.4	46
17	Characterization and structure-activity relationship analysis of a class of antiviral compounds that directly bind dengue virus capsid protein and are incorporated into virions. Antiviral Research, 2018, 155, 12-19.	4.1	19
18	Endochin-Like Quinolones Exhibit Promising Efficacy Against Neospora Caninum in vitro and in Experimentally Infected Pregnant Mice. Frontiers in Veterinary Science, 2018, 5, 285.	2.2	17

AARON NILSEN

#	Article	lF	CITATIONS
19	MR1 displays the microbial metabolome driving selective MR1-restricted T cell receptor usage. Science Immunology, 2018, 3, .	11.9	113
20	Targeted Structure–Activity Analysis of Endochin-like Quinolones Reveals Potent Qi and Qo Site Inhibitors of <i>Toxoplasma gondii</i> and <i>Plasmodium falciparum</i> Cytochrome <i>bc</i> ₁ and Identifies ELQ-400 as a Remarkably Effective Compound against Acute Experimental Toxoplasmosis. ACS Infectious Diseases, 2018, 4, 1574-1584.	3.8	32
21	A Novel Agonist of the TRIF Pathway Induces a Cellular State Refractory to Replication of Zika, Chikungunya, and Dengue Viruses. MBio, 2017, 8, .	4.1	38
22	Genetic Evidence for Cytochrome <i>b</i> Q _i Site Inhibition by 4(1 <i>H</i>) Tj ETQq0 0 0 rgBT/C Chemotherapy, 2017, 61, .)verlock 10 3.2	0 Tf 50 627 Tc 46
23	Alkoxycarbonate Ester Prodrugs of Preclinical Drug Candidate ELQ-300 for Prophylaxis and Treatment of Malaria. ACS Infectious Diseases, 2017, 3, 728-735.	3.8	38
24	Radical cure of experimental babesiosis in immunodeficient mice using a combination of an endochin-like quinolone and atovaquone. Journal of Experimental Medicine, 2016, 213, 1307-1318.	8.5	74
25	Atovaquone and ELQ-300 Combination Therapy as a Novel Dual-Site Cytochrome <i>bc</i> ₁ Inhibition Strategy for Malaria. Antimicrobial Agents and Chemotherapy, 2016, 60, 4853-4859.	3.2	50
26	Targeting the Cytochrome <i>bc</i> ₁ Complex of Leishmania Parasites for Discovery of Novel Drugs. Antimicrobial Agents and Chemotherapy, 2016, 60, 4972-4982.	3.2	28
27	Characterization of a Novel Human-Specific STING Agonist that Elicits Antiviral Activity Against Emerging Alphaviruses. PLoS Pathogens, 2015, 11, e1005324.	4.7	103
28	ELQ-300 Prodrugs for Enhanced Delivery and Single-Dose Cure of Malaria. Antimicrobial Agents and Chemotherapy, 2015, 59, 5555-5560.	3.2	62
29	Inhibition of Cytochrome bc 1 as a Strategy for Single-Dose, Multi-Stage Antimalarial Therapy. American Journal of Tropical Medicine and Hygiene, 2015, 92, 1195-1201.	1.4	34
30	Subtle Changes in Endochin-Like Quinolone Structure Alter the Site of Inhibition within the Cytochrome <i>bc</i> ₁ Complex of Plasmodium falciparum. Antimicrobial Agents and Chemotherapy, 2015, 59, 1977-1982.	3.2	61
31	Discovery, Synthesis, and Optimization of Antimalarial 4(1 <i>H</i>)-Quinolone-3-Diarylethers. Journal of Medicinal Chemistry, 2014, 57, 3818-3834.	6.4	100
32	Quinolone-3-Diarylethers: A New Class of Antimalarial Drug. Science Translational Medicine, 2013, 5, 177ra37.	12.4	187
33	Sontochin as a Guide to the Development of Drugs against Chloroquine-Resistant Malaria. Antimicrobial Agents and Chemotherapy, 2012, 56, 3475-3480.	3.2	21
34	Endochin-like quinolones are highly efficacious against acute and latent experimental toxoplasmosis. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 15936-15941.	7.1	173
35	lodothyronamines are Oxidatively Deaminated to lodothyroacetic Acids in vivo. ChemBioChem, 2009, 10, 361-365.	2.6	47
36	A Subtype-Selective, Use-Dependent Inhibitor of Native AMPA Receptors. Journal of the American Chemical Society, 2007, 129, 4902-4903.	13.7	32

AARON NILSEN

#	Article	IF	CITATIONS
37	Ketone Functionalized Nitroxides:Â Synthesis, Evaluation ofN-Alkoxyamine Initiators, and Derivatization of Polymer Termini. Macromolecules, 2007, 40, 7848-7854.	4.8	13
38	Nitroxide-mediated polymerization to form symmetrical ABA triblock copolymers from a bidirectional alkoxyamine initiator. Polymer, 2007, 48, 2564-2571.	3.8	27
39	The Synthesis and Evaluation of New α-Hydrogen Nitroxides for â€~Living' Free Radical Polymerization. Synthesis, 2005, 2005, 1496-1506.	2.3	21
40	Stereochemical Studies of Chiral Acyclic Nitroxides Coupling with a Prochiral Radical. Synthetic Communications, 2004, 34, 2433-2442.	2.1	3